Literature DB >> 2878679

The action of a dopamine (DA1) receptor agonist, fenoldopam in human vasculature in vivo and in vitro.

A Hughes, S Thom, G Martin, D Redman, S Hasan, P Sever.   

Abstract

This study was designed to investigate dopaminergic mechanisms in human vasculature using the selective vascular dopamine receptor agonist fenoldopam in vivo and in vitro. In vivo, forearm blood flow was measured plethysmographically and in vitro isolated rings of human blood vessels from a variety of sites were used for tissue bath studies. Intra-arterial fenoldopam markedly increased forearm blood flow, this effect was antagonised by (R) sulpiride, a vascular dopamine (DA1) antagonist, but not by metoclopramide, a neuronal (DA2) antagonist, or by guanethidine, an adrenergic neurone blocking agent. In vitro, fenoldopam relaxed preconstricted human renal, mesenteric and lumbar arteries, but not saphenous vein in a concentration dependent manner. (RS) sulpiride and SCH 23390 competitively antagonised this effect. These studies demonstrate the presence of a vasodilatory vascular dopamine receptor in man both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878679      PMCID: PMC1401189          DOI: 10.1111/j.1365-2125.1986.tb02932.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  The role of sympathetic nervous system in the vascular actions of dopamine.

Authors:  M F Lokhandwala; B S Jandhyala
Journal:  J Pharmacol Exp Ther       Date:  1979-07       Impact factor: 4.030

Review 2.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

3.  Correlation of the directly observed responses of mesenteric vessles of the rat to nerve stimulation and noradrenaline with the distribution of adrenergic nerves.

Authors:  J B Furness; J M Marshall
Journal:  J Physiol       Date:  1974-05       Impact factor: 5.182

4.  Dopamine receptors in human basilar arteries.

Authors:  C Forster; G M Drew; A Hilditch; E T Whalley
Journal:  Eur J Pharmacol       Date:  1983-02-18       Impact factor: 4.432

5.  Comparison of the effects of dopamine, isoproterenol, norepinephrine and bradykinin on canine renal and femoral blood flow.

Authors:  J L McNay; L I Goldberg
Journal:  J Pharmacol Exp Ther       Date:  1966-01       Impact factor: 4.030

6.  Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.

Authors:  R A Hahn; J R Wardell; H M Sarau; P T Ridley
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

Review 7.  Minireview. Evidence that dopamine is a neurotransmitter in peripheral tissues.

Authors:  Z Lackovic; N H Neff
Journal:  Life Sci       Date:  1983-04-11       Impact factor: 5.037

8.  A new oral renal vasodilator, fenoldopam.

Authors:  R M Stote; J W Dubb; R G Familiar; B B Erb; F Alexander
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

9.  Evidence for dopaminergic vasodilator innervation of the canine paw pad.

Authors:  C Bell; W J Lang
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

Review 10.  Metoclopramide: pharmacology and clinical application.

Authors:  R Albibi; R W McCallum
Journal:  Ann Intern Med       Date:  1983-01       Impact factor: 25.391

View more
  12 in total

1.  Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit.

Authors:  M Emerson; W Paul; C P Page
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Role of dopaminergic and adrenergic receptors in the pathogenesis of arterial lesions induced by fenoldopam mesylate and dopamine in the rat.

Authors:  W D Kerns; E Arena; D G Morgan
Journal:  Am J Pathol       Date:  1989-08       Impact factor: 4.307

3.  A single dose study of the effects of fenoldopam and enalapril in mild hypertension.

Authors:  T M MacDonald; R F Jeffrey; S Freestone; M R Lee
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Metoclopramide, domperidone and dopamine in man: actions and interactions.

Authors:  T M MacDonald
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Vasodilator responses to dopamine in rat perfused mesentery are age-dependent.

Authors:  J C Wanstall; S R O'Donnell
Journal:  Br J Pharmacol       Date:  1989-09       Impact factor: 8.739

6.  Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.

Authors:  Kenshi Matsumoto; Masaki Yoshida; Karl-Erik Andersson; Petter Hedlund
Journal:  Br J Pharmacol       Date:  2005-09       Impact factor: 8.739

7.  Effects of intravenous fenoldopam (SK&F 82526-J) on blood pressure in severe hypertension. SK&F Fenoldopam Working Group.

Authors: 
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

Review 8.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

9.  Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients.

Authors:  R R Weber; C E McCoy; J A Ziemniak; E D Frederickson; L I Goldberg; M B Murphy
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

10.  Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.

Authors:  S Aronson; L I Goldberg; S Roth; D Glock; J Moss; M F Roizen
Journal:  Can J Anaesth       Date:  1990-04       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.